Institut Pasteur Korea has signed a memorandum of understanding (MOU) with four Pohang University of Science and Technology (POSTECH)-affiliated research institutes with the aim of pursuing joint research on mRNA vaccine and treatment development.
Novel vaccines that can effectively target both coronaviruses and influenza viruses would be desirable to counteract the significant health burden these respiratory pathogens pose.
Azole derivatives have been used as antifungal drugs in clinical practice for many years. However, limitations such as drug-drug interactions, severe adverse events from prolonged use, and high resistance prevalence highlight the urgent need for new therapeutic options to treat the rising number of invasive fungal infections.
First, the good news about pandemics – and in 2024, there was big “good news.” Science Magazine named lenacapavir (Gilead Sciences Inc.) as the Breakthrough of the Year. In two separate trials, lenacapavir prevented HIV transmission with 100% efficacy in cisgender African women and 99.9% efficacy in men and gender-diverse persons when administered twice a year.
Basilea Pharmaceutica Ltd. has been awarded an additional $7.3 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) to support the progression of the company’s novel antibiotic candidate, BAL-2420.
University of Washington has divulged compounds acting as methionyl-tRNA synthetase (bacterial) inhibitors reported to be useful for the treatment of bacterial and protozoal infections.
Tigatx Inc. has been awarded up to $33.5 million in funding by the Advanced Research Projects Agency for Health and a 2-year $2 million Direct to Phase II Small Business Innovation Research grant from the National Cancer Institute.
Antiretroviral therapy effectively suppresses HIV viral loads to undetectable levels but cannot eliminate the integration of viral DNA into the host cell genome.
SK Bioscience has received approval from the Human Research Ethics Committee in Australia for a phase I/II trial of its mRNA-based Japanese encephalitis vaccine candidate, GBP-560.